Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.

City Therapeutics will develop an RNAi clinical candidate for intravitreal administration targeting retinal diseases, including geographic atrophy. Bausch + Lomb will manage IND-enabling studies, ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial ...

After hours: January 29 at 6:13:01 PM EST Loading Chart for BLCO ...

VAUGHAN, Ontario, January 22, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...

Bausch, which has been working to sell its profitable eye-care business Bausch + Lomb and refinance debt, tapped bankers from Evercore Inc. to advise it on financial options, according to people ...